90495-99-1

Basic information

• Product Name: 2-[N-[2-(BOC-AMINO)ETHYL]AMINO]ACETIC ACID
• Synonyms: 2-[N-[2-(BOC-AMINO)ETHYL]AMINO]ACETIC ACID;2-[[2-(Boc-amino)ethyl]amino]acetic acid;N-[2-[[(1,1-Dimethylethoxy)carbonyl]amino]ethyl]glycine;([2-[(tert-Butoxycarbonyl)amino]ethyl]amino)acetic acid
• CAS NO: 90495-99-1
• Molecular Formula: C₉H₁₈N₂O₄
• Molecular Weight: 218.251
• Mol File: 90495-99-1.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[N-[2-(BOC-AMINO)ETHYL]AMINO]ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[N-[2-(BOC-AMINO)ETHYL]AMINO]ACETIC ACID(90495-99-1)
• EPA Substance Registry System: 2-[N-[2-(BOC-AMINO)ETHYL]AMINO]ACETIC ACID(90495-99-1)

Safety Data

• Hazardous Substances Data: 90495-99-1(Hazardous Substances Data)

Usage

General Description

The chemical 2-[N-[2-(BOC-AMINO)ETHYL]AMINO]ACETIC ACID is a compound with the molecular formula C11H21N3O5. It is an amino acid derivative that contains a BOC-protected amino group. 2-[N-[2-(BOC-AMINO)ETHYL]AMINO]ACETIC ACID is often used in the synthesis of peptides and other organic compounds due to its ability to act as a building block for larger molecules. It has a wide range of potential applications in drug development, chemical research, and pharmaceutical manufacturing due to its versatile nature and usefulness as a reagent in organic synthesis.

Upstream product

• 72648-80-7 ethyl 2-[2-(tert-butoxycarbonylamino)ethyl-[3-[[4-(4,5-difluoro-2-methylsulfanyl-phenyl)phenoxy]methyl]benzoyl]amino]acetate 
• 57260-73-8 N-BOC-1,2-diaminoethane 
• 298-12-4 Glyoxilic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 174799-52-1 tert-butyl {2-[benzylamino]ethyl}carbamate 
• 24123-14-6 N-(2-Aminoethyl)glycine 
• 79-11-8 chloroacetic acid 
• 158663-62-8 N-((tert-butoxycarbonyl)-aminoethyl)glycine benzyl ester 
• 174799-94-1 benzyl 2-(benzyl{2-[(tert-butoxycarbonyl)amino]ethyl}amino)acetate 

Downstream Products

• 141743-15-9 2-((((9H-fluoren-9-yl)methoxy)carbonyl)(2-((tert-butoxycarbonyl)amino)ethyl)amino)acetic acid 
• 1025696-29-0 N-[2-(N-Boc)aminoethyl]-2-(4-dimethylaniline)-3,4-fulleropyrrolidine 
• 1025696-38-1 N-[2-(N-Boc)aminoethyl]-2-(5-(4-phenyl)-10,15,20-tris(3,5-di-tert-butylphenyl)porphyrin)zinc(II)-3,4-fulleropyrrolidine 
• 406683-60-1 (E)-17-[N-[2-(tert-Butyloxycarbonylamino)ethyl]-N-fluorenylmethyloxycarbonylglycinyloxy]-4,7,10,13-tetraoxa-15-heptadecenoic acid phenacyl ester 
• 169287-77-8 Boc-PNA(G^Z)-OH 
• 34046-07-6 N-benzyloxycarbonyl-N-(2-t.butoxycarbonylaminoethyl)glycine 
• 139166-80-6 N-(2-t-butoxycarbonylaminoethyl)-N-(thymin-1-ylacetyl)glycine 

Relevant articles and documents

Synthesis of camptothecin-amino acid carbamate linkers

A more convenient and facile approach for the synthesis and production of camptothecin-amino acids carbamate linkers, that can be used in the synthesis of bioconjugate peptides JF-10-81, JF-10-71, and other peptide analogs designed to target somatostatin receptors has been described. Springer-Verlag 2011.

Design, development and synthesis of a novel labeled PNA monomer incorporated in DNA-hexamer to act as a hybridization probe by FRET

A novel PNA monomer with adenine nucleobase and a modified backbone with charged -N+-H and a methylene substituted for 2 bond on the lefthand side sign C=O in the linker arm has been synthesised. This modified PNA monomer is further linked with

Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14)

The osteogenic growth peptide (OGP) is a key factor in the mechanism of the systemic osteogenic response to local bone marrow injury. When administered in vivo, OGP stimulates osteogenesis and hematopoiesis. The C-terminal pentapeptide OGP(10-14) is the minimal amino acid sequence that retains the full OGP-like activity. Apparently, it is also the physiologic active form of OGP. Residues Tyr10, Phe12, Gly13, and Gly14 of OGP are essential for the OGP(10-14) activity. The present study explored the functional role of the peptide bonds, carboxyl and amino terminal groups, and conformational freedom in OGP(10-14). Transformations replacing the peptide bonds with surrogates such as ψ(CH2NH), ψ(CONMe), and ψ(CH2CH2) demonstrated that amide bonds do not contribute significantly to OGP(10-14) bioactivity. End-to-end cyclization yielded the fully bioactive cyclic pentapeptide c(Tyr-Gly-Phe-Gly-Gly). The retroinverso analogue c(Gly-Gly-phe-Gly-tyr), a cyclostereoisomer of c(Tyr-Gly-Phe-Gly-Gly), is at least as potent as the parent cyclic pentapeptide. The unique structure-activity relations revealed in this study suggest that the spatial presentation of the Tyr and Phe side chains has a major role in the productive interaction of OGP(10-14) and its truncated and conformationally constrained analogues with their cognate cellular target.